Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptose Biosciences Inc.APTO · Entity 33387 | Senior VP, CFO, and CBO | January 18, 2022 | January 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptose Biosciences Inc.
Report date January 18, 2022 · Filed January 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2032-01-17 | Direct | 600,000 |
Reported balance
After 2022-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-18 · Grant · Acquired 600,000 · Balance 600,000 F1: Fifty percent (50%) of the options vest on 1/18/2023; the remaining 50% vest as follows: 1/3 on 1/18/2024; 1/3 on 1/18/2025; and 1/3 on 1/18/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty percent (50%) of the options vest on 1/18/2023; the remaining 50% vest as follows: 1/3 on 1/18/2024; 1/3 on 1/18/2025; and 1/3 on 1/18/2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ImageneBio, Inc.
Report date July 25, 2025 · Filed July 29, 2025
Section 16 reporting ended · disclosed 2025-07-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,146 |
Ending reported balance
After 2025-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-07-28 · Grant · Acquired 15,776 · Balance 15,776 F1: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. Row 2 · 2025-07-28 · Tax withholding · Disposed 4,630 · Balance 11,146 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-25 · Disposition to issuer · Disposed 181,000 · Balance 0 F1: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-25 · Disposition to issuer · Disposed 105,000 · Balance 0 F1: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-25 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-25 · Disposition to issuer · Disposed 397,199 · Balance 0 F1: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2025 Filed Jul 29, 2025 21:32 UTC | ImageneBio, Inc. IMA · Entity 7139 | Tax withholdingCommon Stock | 4,630 | $17.16 | $79,450.80 |
DisclosureSEC source: 0000950170-25-099848 · ownership.xml · nonDerivative · entry 2 Marango Jotin · CIK 0001777513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,146 Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 21:32 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantCommon Stock | 15,776 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-099848 · ownership.xml · nonDerivative · entry 1 Marango Jotin · CIK 0001777513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,776 F1 · price: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 21:32 UTC | ImageneBio, Inc. IMA · Entity 7139 | Disposition to issuerStock Option (Right to Buy) · Derivative | 397,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-099848 · ownership.xml · derivative · entry 5 Marango Jotin · CIK 0001777513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 397,199 shares Expires not disclosed F1 · derivative.exercise_price: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. F1 · derivative.exercise_date: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. F1 · derivative.expiration_date: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 21:32 UTC | ImageneBio, Inc. IMA · Entity 7139 | Disposition to issuerStock Option (Right to Buy) · Derivative | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-099848 · ownership.xml · derivative · entry 4 Marango Jotin · CIK 0001777513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires not disclosed F1 · derivative.exercise_price: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. F1 · derivative.exercise_date: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. F1 · derivative.expiration_date: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 21:32 UTC | ImageneBio, Inc. IMA · Entity 7139 | Disposition to issuerStock Option (Right to Buy) · Derivative | 181,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-099848 · ownership.xml · derivative · entry 3 Marango Jotin · CIK 0001777513 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 181,000 shares Expires not disclosed F1 · derivative.exercise_price: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. F1 · derivative.exercise_date: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. F1 · derivative.expiration_date: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 17:08 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 181,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0000950170-24-010601 · ownership.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · CFO & Head of Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,000 Underlying: Common Stock · 181,000 shares Expires 2034-02-01 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:15 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0000899243-23-000986 · doc4.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 25, 2022 Filed Apr 25, 2022 18:54 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 397,199 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0000899243-22-015586 · doc4.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · CFO & Head of Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,199 Underlying: Common Stock · 397,199 shares Expires 2032-04-25 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 25, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:17 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Stock Option · Derivative | 600,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-22-001379 · doc1.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, CFO, and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Shares · 600,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on 1/18/2023; the remaining 50% vest as follows: 1/3 on 1/18/2024; 1/3 on 1/18/2025; and 1/3 on 1/18/2026. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:57 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantPerformance Stock Option · Derivative | 200,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001567619-21-016232 · doc1.xml · derivative · entry 2 Marango Jotin · CIK 0001777513 · Senior VP, CFO, and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2031-08-19 F1 · derivative.exercise_date: The options were granted on August 19, 2021 and vest upon the earlier of (i) certain performance conditions or (ii) August 19, 2025, subject to Reporting Person's continued employment with the Issuer. F3 · derivative.exercise_date: Options vest in connection with licensing and partnering events. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:57 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantPerformance Stock Option · Derivative | 200,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001567619-21-016232 · doc1.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, CFO, and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2031-08-19 F1 · derivative.exercise_date: The options were granted on August 19, 2021 and vest upon the earlier of (i) certain performance conditions or (ii) August 19, 2025, subject to Reporting Person's continued employment with the Issuer. F2 · derivative.exercise_date: Options vest in tranches connected with financing events. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:19 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Stock Option (Right to Buy) · Derivative | 343,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001567619-21-000640 · doc1.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,000 Underlying: Common Shares · 343,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: The options were granted on January 4, 2021. One-half of the options vest on January 4, 2022. The remaining one-half of the options vest as follows: 1/3 on January 4, 2023; 1/3 on January 4, 2024; and 1/3 on January 4, 2025. Read SEC document |
| July 10, 2020 Filed Jul 10, 2020 22:53 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | SaleCommon Shares | 62,835 | $6.05 | $380,151.75 |
DisclosureSEC source: 0001567619-20-013185 · doc1.xml · nonDerivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,219 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of 120,000 restricted stock units, previously reported on a Form 4/A filed with Securities and Commission on March 10, 2020. Read SEC document |
| July 02, 2020 Filed Jul 3, 2020 00:08 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | SaleCommon Shares | 20,946 | $6.34 | $132,793.45 |
DisclosureSEC source: 0001567619-20-012894 · doc1.xml · nonDerivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,054 F1 · shares: Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of 40,000 restricted stock units, previously reported on a Form 4/A filed with Securities and Commission on May 7, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Aptose Biosciences Inc., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:33 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Shares | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006192 · doc1.xml · nonDerivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Restricted stock units which shall vest on June 10, 2020. Read SEC document |
| March 10, 2020 Filed May 7, 2020 20:38 UTC Amendment | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Shares | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009219 · doc1.xml · nonDerivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Restricted stock units previously granted with original vesting date of June 10, 2020, shall now vest on July 10, 2020. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 02:47 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Option Grant · Derivative | 400,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001567619-20-001983 · doc1.xml · derivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on 1/31/2021; the remaining 50% vest as follows: 1/3 on 1/31/2022; 1/3 on 1/31/2023; and 1/3 on 1/31/2024. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:21 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantEmployee Stock Options (right to buy) · Derivative | 320,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012814 · doc1.xml · derivative · entry 2 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2029-06-03 F2 · derivative.exercise_date: One half of the options will vest on 6/3/2020; the remaining one-half will vest as follows: 1/3 on 6/3/2021; 1/3 on 6/3/2022; and 1/3 on 6/3/2023. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:21 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Shares | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012814 · doc1.xml · nonDerivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F1 · shares: Restricted stock units which shall vest as follows: One-half on 9/3/2019 and one-half on 6/3/2020. Read SEC document |
| June 03, 2019 Filed May 7, 2020 21:24 UTC Amendment | Aptose Biosciences Inc. APTO · Entity 33387 | GrantCommon Shares | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009232 · doc1.xml · nonDerivative · entry 1 Marango Jotin · CIK 0001777513 · Senior VP, Chief Bus. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F1 · shares: Restricted stock units previously granted with the following original vesting dates: One-half vesting on September 3, 2019, and one-half vesting on June 3, 2020. The second half of the grant shall now vest on July 2, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.